1. Lythgoe KEMF, Anderson PJ, Smith T, Gordon I. Biokinetic Behavior of Technetium—99m-DMSA in Children. J Nucl Med 1996; 37: 1331-35.
2. Sfakianakis GN, Cavagnaro F, Zilleruelo G, Abitbol C, Montane B, Georgiou M, et al. Diuretic MAG3 scintigraphy (F0) in acute pyelonephritis: regional parenchymal dysfunction and comparison with DMSA. J Nuclear Med 2000; 41(12): 1955-63.
3. Treves ST, Baker A, Fahey FH, Cao X, Davis RT, Drubach LA, et al. Nuclear medicine in the first year of life. J Nuclear Med 2011; 52(6): 905-25.
4. Sgouros G, Frey EC, Bolch WE, Wayson MB, Abadia AF, Treves ST. An approach for balancing diagnostic image quality with cancer risk: application to pediatric diagnostic imaging of 99mTc-dimercaptosuccinic acid. J Nuclear Med 2011; 52(12): 1923-29.
5. Eberlein U, Bröer JH, Vandevoorde C, Santos P, Bardiès M, Bacher K, et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine–a review. European J Nuclear Med and molecular imaging 2011; 38(12): 2269-81.
6. Shahbazi-Gahrouei D, Nikzad S. Determination of organ doses in radioiodine therapy using medical internal radiation dosimetry (MIRD) method. Iran J Radiat Res 2011; 8(4): 249-52.
7. Grimes J, Celler A. Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques. Medical physics 2014; 41(9): 092501.
8. Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, et al. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors. J Nuclear Med 2011; 52(9): 1474-81.
9. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG. J Nuclear Med 2001; 42(11): 1713-21.
10. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J nuclear Med 2003; 44(3): 465-74.
11. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nuclear Med 2005; 46(6): 1023-7.
12. Momennezhad M, Nasseri S, Zakavi SR, Parach AA, Ghorbani M, Asl RG. A 3D Monte Carlo Method for Estimation of Patient-specific Internal Organs Absorbed Dose for 99mTc-hynic-Tyr3-octreotide Imaging. World J nuclear Med 2016; 15(2): 114.
13. Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[18 F] Fluoro-A-85380 in human PET imaging studies. Nuclear Med Bio 2005; 32(8): 869-74.
14. Marcatili S, Villoing D, Mauxion T, McParland B, Bardiès M. Model-based versus specific dosimetry in diagnostic context: Comparison of three dosimetric approaches. Med physics 2015; 42(3): 1288-96.
15. Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging–based internal dosimetry. J Nuclear Med 2007; 48(6): 1008-16.
16. Siegel JA, Thomas SR, Stubbs JB, Stabin MG. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nuclear Med 1999; 40(2): 37S.
17. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, et al. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning—patient studies. Med physics 2009; 36(5): 1595-1601.
18. Parach AA, Rajabi H, Askari MA. Paired organs—Should they be treated jointly or separately in internal dosimetry? Med physics 2011; 38(10): 5509-21.
19. Smith T, Evans K, Lythgoe MF, Anderson PJ, Gordon I. Radiation Dosimetry of Technetium-99m—DMSA. J Nucl Med 1996; 37: 1336-42.
20. Mattsson S. Patient dosimetry in nuclear medicine. Radiation protection dosimetry 2015: ncv061.